Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
© 2025 Recce Pharmaceuticals